<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115749</url>
  </required_header>
  <id_info>
    <org_study_id>9755</org_study_id>
    <nct_id>NCT03115749</nct_id>
  </id_info>
  <brief_title>Intestinal Mesenchymal Stem Stells and Inflammatory Bowel Diseases</brief_title>
  <acronym>COSMIC</acronym>
  <official_title>Characterization of Mesenchymal Stem Cells From the Colon and Small Intestine of Patients With Inflammatory Bowel Disease - The COSMIC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The exact origin of inflammatory bowel disease (IBD) is still unknown. The current hypothesis&#xD;
      is that IBD is secondary to an abnormal intestinal immun response directed to all or part of&#xD;
      the intestinal flora in genetically predisposed individuals. Several experimental studies&#xD;
      have demonstrated the ability of mesenchymal stem cells (MSCs) from bone marrow or adipose&#xD;
      tissue origin to control intestinal inflammation in animal models. However, to date, there&#xD;
      are no data regarding the functions of resident MSCs in the colon and small intestine of IBD&#xD;
      patients. We hypothesize that dysfunction of resident intestinal MSCs contributes to the&#xD;
      disruption of intestinal homeostasis in patients with IBD causing the development of&#xD;
      intestinal inflammation. The aim of this research project is to identify, describe and&#xD;
      characterize at the molecular and functional level MSCs of the colon and small intestine of&#xD;
      patients with Crohn's disease and ulcerative colitis and to compare them with a control&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary and secondary objectives:&#xD;
&#xD;
      Main Objective: Characterize morphologically, molecularly and functionally the MSCs of colon&#xD;
      and small intestine of patients with IBD and compared to MSCs of colon and small intestine of&#xD;
      control patients.&#xD;
&#xD;
      Secondary objectives: To study the reaction of colon and small intestine MHC in patients with&#xD;
      IBD following stimulation with bacterial compounds.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Clinical study exploratory translational physiopathological. Two groups of patients with&#xD;
      Crohn's disease and ulcerative colitis who require colonoscopy or surgery for intestinal&#xD;
      resection will be included. These two groups will be compared to a control group consisting&#xD;
      of patients requiring colonoscopy for screening or intestinal resection for colorectal cancer&#xD;
      or diverticulum.&#xD;
&#xD;
      Intestinal sampling by biopsy during the colonoscopy or with surgical specimen during the&#xD;
      surgery will be performed to isolate the MSCs.&#xD;
&#xD;
      The outcome measures will be a qualitative and quantitative analysis of MSCs by&#xD;
      immunohistochemistry, immunofluorescence, cell proliferation and differentiation, production&#xD;
      of pro- and anti-inflammatory cytokines in the basal state and after bacterial stimulation.&#xD;
&#xD;
      Total of 60 patients (20 in groups, 15 with colonoscopy and 5 with surgical specimens).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proliferation and differentiation of intestinal MSCs in IBD patients.</measure>
    <time_frame>1 month</time_frame>
    <description>Proliferation and differentiation of intestinal MSCs in IBD patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of MSCs between IBD patients and control patients</measure>
    <time_frame>1 month</time_frame>
    <description>Comparison of MSCs between IBD patients and control patients using mmunohistochemistry, immunofluorescence, quantification of pro- and anti-inflammatory cytokines production.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Crohn's disease patient group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis patient group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intestinal biopsies during colonoscopy</intervention_name>
    <description>Intestinal biopsies during colonoscopy</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Crohn's disease patient group</arm_group_label>
    <arm_group_label>Ulcerative colitis patient group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies taken on surgical specimen</intervention_name>
    <description>biopsies taken on surgical specimen after intestinal resection</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Crohn's disease patient group</arm_group_label>
    <arm_group_label>Ulcerative colitis patient group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  For IBD patients :&#xD;
&#xD;
               -  Age between 18 and 75 year old&#xD;
&#xD;
               -  Diagnosis of Crohn's disease or ulcertaive colitis according to internationla&#xD;
                  guidelines&#xD;
&#xD;
               -  Endoscopically active disease&#xD;
&#xD;
               -  Indication for colonoscopy or intestinal resection according to standard of care&#xD;
&#xD;
               -  Written inform consent&#xD;
&#xD;
          -  For control patients :&#xD;
&#xD;
               -  Age between 18 and 75 year old&#xD;
&#xD;
               -  Indication for screening colonoscopy for irritable bowel syndrome, diverticulum&#xD;
                  or colorectal cancer surveillance according to standard of care&#xD;
&#xD;
               -  Indication for intestinal resection for diverticulum or colorectal cancer&#xD;
                  according to standard of care&#xD;
&#xD;
               -  Written inform consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  For IBD patients :&#xD;
&#xD;
               -  Active intestinal infection&#xD;
&#xD;
               -  Confirmed intestinal parasitosis&#xD;
&#xD;
               -  Intestinal stoma&#xD;
&#xD;
          -  For control patients :&#xD;
&#xD;
               -  Active intestinal infection&#xD;
&#xD;
               -  Confirmed intestinal parasitosis&#xD;
&#xD;
               -  Intestinal inflammation at colonoscopy&#xD;
&#xD;
               -  Chronic intestinal inflammation on biopsies&#xD;
&#xD;
               -  Absence of healthy tissue on surgical specimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Pineton de Chambrun</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Pineton de Chambrun</last_name>
    <phone>0467338825</phone>
    <email>g-pinetondechambrun@chu-montpellier.fr</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>ulcerative colitis</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>intestinal inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

